BioXcel Therapeutics (BTAI) Competitors $3.17 +0.06 (+1.93%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$3.16 -0.01 (-0.32%) As of 09/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BTAI vs. IMMP, ANNX, VYGR, LYEL, TKNO, TNXP, SGMT, ACIU, ACRS, and HUMAShould you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include Prima BioMed (IMMP), Annexon (ANNX), Voyager Therapeutics (VYGR), Lyell Immunopharma (LYEL), Alpha Teknova (TKNO), Tonix Pharmaceuticals (TNXP), Sagimet Biosciences (SGMT), AC Immune (ACIU), Aclaris Therapeutics (ACRS), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry. BioXcel Therapeutics vs. Its Competitors Prima BioMed Annexon Voyager Therapeutics Lyell Immunopharma Alpha Teknova Tonix Pharmaceuticals Sagimet Biosciences AC Immune Aclaris Therapeutics Humacyte Prima BioMed (NASDAQ:IMMP) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk. Do institutionals and insiders hold more shares of IMMP or BTAI? 2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by company insiders. Comparatively, 21.2% of BioXcel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has better earnings & valuation, IMMP or BTAI? Prima BioMed has higher revenue and earnings than BioXcel Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrima BioMed$6.69M37.96-$39.78MN/AN/ABioXcel Therapeutics$2.27M22.36-$59.60M-$12.64-0.25 Do analysts rate IMMP or BTAI? Prima BioMed presently has a consensus price target of $7.00, suggesting a potential upside of 304.62%. BioXcel Therapeutics has a consensus price target of $39.75, suggesting a potential upside of 1,153.94%. Given BioXcel Therapeutics' higher possible upside, analysts plainly believe BioXcel Therapeutics is more favorable than Prima BioMed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 Does the media refer more to IMMP or BTAI? In the previous week, BioXcel Therapeutics had 14 more articles in the media than Prima BioMed. MarketBeat recorded 16 mentions for BioXcel Therapeutics and 2 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 0.86 beat BioXcel Therapeutics' score of 0.77 indicating that Prima BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioXcel Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is IMMP or BTAI more profitable? Prima BioMed has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -5,869.82%. Company Net Margins Return on Equity Return on Assets Prima BioMedN/A N/A N/A BioXcel Therapeutics -5,869.82%N/A -134.45% Which has more volatility & risk, IMMP or BTAI? Prima BioMed has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. SummaryPrima BioMed beats BioXcel Therapeutics on 8 of the 14 factors compared between the two stocks. Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BTAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTAI vs. The Competition Export to ExcelMetricBioXcel TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.79M$3.15B$5.80B$10.18BDividend YieldN/A2.33%5.73%4.61%P/E Ratio-0.2521.2474.8626.39Price / Sales22.36467.22543.01125.40Price / CashN/A44.4425.8129.91Price / Book-0.119.6413.256.28Net Income-$59.60M-$53.20M$3.29B$270.38M7 Day Performance-11.45%0.07%0.07%1.89%1 Month Performance-42.15%4.27%4.60%6.01%1 Year Performance-69.04%9.62%72.96%25.26% BioXcel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTAIBioXcel Therapeutics3.9554 of 5 stars$3.17+1.9%$39.75+1,153.9%-70.9%$49.79M$2.27M-0.2590Analyst ForecastShort Interest ↑IMMPPrima BioMed1.4601 of 5 stars$1.72+4.2%$7.00+307.0%-34.5%$242.20M$6.69M0.002,021ANNXAnnexon2.6058 of 5 stars$2.21+1.8%$12.50+465.6%-65.4%$238.45MN/A-1.7160Positive NewsVYGRVoyager Therapeutics4.0342 of 5 stars$4.26+0.5%$13.25+211.0%-32.6%$235.19M$80M-2.30100News CoveragePositive NewsAnalyst ForecastGap UpLYELLyell Immunopharma2.7129 of 5 stars$13.03+7.2%$15.00+15.1%-46.6%$233.42M$60K-0.54270Positive NewsTKNOAlpha Teknova2.8114 of 5 stars$4.35-0.2%$10.00+129.9%+3.0%$233.33M$37.74M-10.36240Positive NewsTNXPTonix Pharmaceuticals3.2757 of 5 stars$25.29-4.7%$70.00+176.8%+77.0%$232.65M$10.09M-0.6450SGMTSagimet Biosciences3.3539 of 5 stars$7.03-1.1%$25.67+265.1%+71.0%$231.23M$2M-3.848News CoverageAnalyst DowngradeACIUAC Immune2.6068 of 5 stars$2.20-3.5%$10.00+354.5%-22.0%$228.94M$31.02M-3.79140Positive NewsACRSAclaris Therapeutics2.6712 of 5 stars$2.08-1.0%$8.71+319.0%+55.9%$227.50M$18.72M-1.52100HUMAHumacyte3.1264 of 5 stars$1.41-1.4%$9.75+591.5%-72.9%$226.47M$1.57M-3.13150News CoveragePositive NewsAnalyst ForecastGap Up Related Companies and Tools Related Companies Prima BioMed Alternatives Annexon Alternatives Voyager Therapeutics Alternatives Lyell Immunopharma Alternatives Alpha Teknova Alternatives Tonix Pharmaceuticals Alternatives Sagimet Biosciences Alternatives AC Immune Alternatives Aclaris Therapeutics Alternatives Humacyte Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTAI) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored“Godfather of AI’s” dire warningAI pioneer Geoffrey Hinton warns the technology could create massive unemployment and widen inequality, but Po...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
